• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Hercules Capital Announces Date of 2024 Annual Meeting of Stockholders

    5/13/24 6:00:00 AM ET
    $HCXY
    $HTGC
    Investment Managers
    Finance
    Get the next $HCXY alert in real time by email

    Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2024 Annual Meeting of Stockholders by virtual meeting on Thursday, June 20, 2024 at 9:00 a.m. (Pacific Time). The proxy statement for the meeting was filed on April 23, 2024 and mailed to stockholders of record as of April 19, 2024.

    2024 Annual Meeting of Stockholders

    June 20, 2024 at 9:00 a.m. Pacific Time

    Virtual Meeting via Internet: www.virtualshareholdermeeting.com/HTGC2024

    Matters to be voted on include: 1) election of three independent directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock at a price below its then-current NAV per share, and 4) ratification of the Company's independent public accounting firm.

    About Hercules Capital, Inc.

    Hercules Capital, Inc. (NYSE:HTGC) is the leading and largest specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries. Since inception (December 2003), Hercules has committed more than $20.0 billion to over 650 companies and is the lender of choice for entrepreneurs and venture capital firms seeking growth capital financing. Companies interested in learning more about financing opportunities should contact [email protected], or call 650.289.3060.

    Hercules, through its wholly owned subsidiary business, Hercules Adviser LLC (the "Adviser Subsidiary"), also maintains an asset management business through which it manages investments for external parties ("Adviser Funds"). The Adviser Subsidiary is registered as an investment adviser under the Investment Advisers Act of 1940.

    Hercules' common stock trades on the New York Stock Exchange (NYSE) under the ticker symbol "HTGC." In addition, Hercules has one retail bond issuance of 6.25% Notes due 2033 (NYSE:HCXY).

    Additional Information

    This communication may be deemed solicitation material in respect of the proposals described above (the "proposals"). In connection with the proposals, the Company has filed, and intends to file, relevant materials with the Securities and Exchange Commission (the "SEC"). Promptly after filing its definitive proxy statements with the SEC, the Company will mail the definitive proxy statements and proxy cards to each stockholder entitled to vote at the stockholder meetings relating to such matters. STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO), AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE, BECAUSE THESE MATERIALS WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PROPOSALS. The preliminary proxy statement, the definitive proxy statements and other relevant materials (when they become available), and any other documents filed by the Company with the SEC, may be obtained free of charge at the SEC's website (http://www.sec.gov), at the Company's website (http://www.htgc.com), or by writing to Hercules Capital, Inc. c/o Kiersten Zaza Botelho, Secretary, 31 St. James Avenue, Suite 1005, Boston, Massachusetts, 02116 (telephone number 617-314-9973).

    The Company and its directors and officers may be deemed to be participants in the solicitation of proxies from the Company's stockholders with respect to the proposals. Information about the Company's directors and officers, as well as the identity of other potential participants, and their respective direct or indirect interests in such matters, by security holdings or otherwise, are set forth in the preliminary proxy statement and will be set forth in the definitive proxy statements and other materials to be filed with SEC.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240513291201/en/

    Get the next $HCXY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HCXY
    $HTGC

    CompanyDatePrice TargetRatingAnalyst
    Hercules Capital Inc.
    $HTGC
    12/12/2024$19.50 → $21.50Mkt Perform → Outperform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    1/16/2024$17.00 → $17.50Buy → Neutral
    Compass Point
    Hercules Capital Inc.
    $HTGC
    11/21/2023$17.00Neutral
    UBS
    Hercules Capital Inc.
    $HTGC
    8/30/2023$17.50Neutral → Buy
    Compass Point
    Hercules Capital Inc.
    $HTGC
    8/4/2023$13.50 → $17.00Underperform → Mkt Perform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    4/6/2023$16.00Neutral → Overweight
    Piper Sandler
    Hercules Capital Inc.
    $HTGC
    3/13/2023$14.50 → $10.50Mkt Perform → Underperform
    Keefe Bruyette
    Hercules Capital Inc.
    $HTGC
    7/29/2022Outperform → Perform
    Oppenheimer
    More analyst ratings

    $HCXY
    $HTGC
    Leadership Updates

    Live Leadership Updates

    See more
    • Revelation Partners Expands Team with Hire of Andrew Olson, Partner, Chief Financial Officer & Chief Operating Officer

      SAUSALITO, Calif., Nov. 29, 2023 /PRNewswire/ -- Revelation Partners, a healthcare investment firm with over $1.5 billion of capital under management, announced today the addition of Andrew Olson as Partner, Chief Financial Officer and Chief Operating Officer. Mr. Olson has an extensive background in the venture capital and funds management industry. His addition to the team will enhance the firm's technical expertise, support the differentiated investment model, and strengthen the firm's ongoing foundation. As the firm's new Chief Financial Officer and Chief Operating Officer

      11/29/23 1:01:00 PM ET
      $HTGC
      $TPVG
      Investment Managers
      Finance
      Other Consumer Services
      Consumer Discretionary
    • Hercules Capital Announces the Appointment of Mr. Nikos Theodosopoulos to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that Nikos Theodosopoulos was appointed to serve as an independent member of its board of directors, effective September 21, 2023. Mr. Theodosopoulos is an experienced corporate executive and board director with more than 38 years in senior management roles in both the financial services and technology industries. Mr. Theodosopoulos will serve on the Company's Audit Committee. "Nikos' combined experienc

      9/25/23 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Announces the Appointment of Ms. DeAnne Aguirre to Its Board of Directors

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced that DeAnne Aguirre was appointed to serve as an independent member of its board of directors, effective June 23, 2022. Ms. Aguirre is an experienced corporate executive and Board Director with more than 30 years in senior leadership managing large and complex domestic and international business units. Ms. Aguirre will serve on the Nominating and Corporate Governance Committee. "As we continue to expand o

      6/24/22 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Subject)

      5/8/23 5:06:26 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G/A filed by Hercules Capital Inc. (Amendment)

      SC 13G/A - Hercules Capital, Inc. (0001280784) (Filed by)

      10/12/22 9:11:00 AM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form SC 13G filed by Hercules Capital Inc.

      SC 13G - Hercules Capital, Inc. (0001280784) (Filed by)

      4/27/22 4:31:08 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital

      GAITHERSBURG, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (NASDAQ:ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that it has entered into an agreement with Hercules Capital, Inc. (NYSE:HTGC), a leader in debt financing for life science companies, for up to $100 million in a credit facility, with a $15 million tranche funded at closing. Additional tranches will become available upon achievement of certain clinical and financial milestones aligned with the Company's pemvidutide development plans and financing needs. Access to this additional capital strengthens Altimmune's ba

      5/13/25 7:00:00 AM ET
      $ALT
      $HTGC
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Investment Managers
      Finance
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Hercules Capital upgraded by Keefe Bruyette with a new price target

      Keefe Bruyette upgraded Hercules Capital from Mkt Perform to Outperform and set a new price target of $21.50 from $19.50 previously

      12/12/24 8:09:58 AM ET
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital downgraded by Compass Point with a new price target

      Compass Point downgraded Hercules Capital from Buy to Neutral and set a new price target of $17.50 from $17.00 previously

      1/16/24 8:29:29 AM ET
      $HTGC
      Investment Managers
      Finance
    • UBS initiated coverage on Hercules Capital with a new price target

      UBS initiated coverage of Hercules Capital with a rating of Neutral and set a new price target of $17.00

      11/21/23 7:31:43 AM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Crowell Gayle A bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 9% to 69,344 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:21:45 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    SEC Filings

    See more
    • Hercules Capital Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits

      8-K - Hercules Capital, Inc. (0001280784) (Filer)

      5/1/25 4:30:18 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form 10-Q filed by Hercules Capital Inc.

      10-Q - Hercules Capital, Inc. (0001280784) (Filer)

      5/1/25 4:16:15 PM ET
      $HTGC
      Investment Managers
      Finance
    • SEC Form DEFA14A filed by Hercules Capital Inc.

      DEFA14A - Hercules Capital, Inc. (0001280784) (Filer)

      4/24/25 5:04:38 PM ET
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Financials

    Live finance-specific insights

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Hercules Capital Announces Date of 2025 Annual Meeting of Stockholders

      Hercules Capital, Inc. (NYSE:HTGC) ("Hercules" or the "Company"), will conduct its 2025 Annual Meeting of Stockholders by virtual meeting on Wednesday, June 18, 2025 at 9:00 a.m. (Eastern Time). The proxy statement for the meeting was filed on April 24, 2025 and mailed to stockholders of record as of April 17, 2025. 2025 Annual Meeting of Stockholders June 18, 2025 at 9:00 a.m. Eastern Time Virtual Meeting via Internet: http://www.virtualshareholdermeeting.com/HTGC2025 Matters to be voted on include: 1) election of three directors, 2) an advisory vote on the compensation of the Company's named executive officers, 3) authorization of the Company to sell or issue shares of its common stock

      5/8/25 6:00:00 AM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance
    • Hercules Capital Reports First Quarter 2025 Financial Results

      Q1 2025 Total Gross Debt and Equity Commitments of $1.02 Billion Q1 2025 Total Gross Fundings of $539.1 Million Q1 2025 Total Investment Income of $119.5 Million Q1 2025 Net Investment Income "NII" of $77.5 Million, or $0.45 per Share Q1 2025 NII of $0.45 per Share, provides 113% Coverage of the Base Cash Distribution Received an Investment Grade Rating Upgrade to BBB (high) from Morningstar DBRS Closed Offering of $287.5 Million of 4.750% Convertible Unsecured Notes due 2028 Conservative Balance Sheet Management with Net GAAP Leverage of 97.4% and Net Regulatory Leverage of 82.7%(1) Inclusive of the Adviser Funds Advised by Hercules Adviser LLC, its Wholly-Owned Subsidiary, Hercule

      5/1/25 4:04:00 PM ET
      $HCXY
      $HTGC
      Investment Managers
      Finance

    $HCXY
    $HTGC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Theodosopoulos Nikos bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 101% to 11,960 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:23 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Loo Wade bought $104,923 worth of shares (5,999 units at $17.49), returned 5,645 shares to the company and was granted 5,645 shares, increasing direct ownership by 5% to 7,504 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:22:04 PM ET
      $HTGC
      Investment Managers
      Finance
    • Director Crowell Gayle A bought $104,923 worth of shares (5,999 units at $17.49), increasing direct ownership by 9% to 69,344 units (SEC Form 4)

      4 - Hercules Capital, Inc. (0001280784) (Issuer)

      5/9/25 4:21:45 PM ET
      $HTGC
      Investment Managers
      Finance